PDCD1 and melanoma: In particular, therapies targeting the immune checkpoint inhibitors programmed cell death protein-1/programmed cell death-ligand 1 (PD-1/PD-L1) interaction positively influenced the outcome of various forms of cancer such as NSCLC and malignant melanoma.